Healthcare stock prices have been pressured by election policy discussions and many believe share prices may continue to be impacted. Over the last three months (ending October 30, 2015), the overall S&P declined 1.4% while the S&P 500-Pharmaceuticals, Biotechnology and Life Sciences Index declined 6.1%, despite the defensive nature of the sector.
M&A advisory, restructuring and insolvency, debt advisory, strategic alternatives, transaction diligence and independent financial opinions.
Kroll’s investment banking practice has extensive experience in M&A deal strategy and structuring, capital raising, transaction advisory services and financial sponsor coverage.
Dedicated coverage and access to M&A deal-flow for financial sponsors.
Kroll’s Transaction Advisory Services platform offers corporate and financial investors with deep accounting and technical expertise, commercial knowledge, industry insight and seamless analytical services throughout the deal continuum.
Kroll has extensive experience raising capital for middle-market companies to support a wide range of transactions.